

Xiang Yan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4159440/publications.pdf>

Version: 2024-02-01

37
papers

740
citations

623734

14
h-index

552781

26
g-index

40
all docs

40
docs citations

40
times ranked

1376
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor- β in B cell responses. <i>Oncogene</i> , 2022, 41, 1434-1444.	5.9	1
2	A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations. <i>Cancer Medicine</i> , 2022, 11, 1026-1036.	2.8	4
3	Carbon Dots in Biomedicine: A Review. <i>ACS Applied Bio Materials</i> , 2022, 5, 2031-2045.	4.6	25
4	Efficacy and safety of dacomitinib in advanced non-small cell lung cancer patients harboring uncommon EGFR mutations: Real-world evidence from China.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21163-e21163.	1.6	0
5	Using multiomics analysis to examine prognostic biomarkers for patients with squamous cell lung carcinoma treated with neoadjuvant therapy of camrelizumab combined with Apatinib.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20563-e20563.	1.6	0
6	Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via promoting M2 macrophages polarization.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20552-e20552.	1.6	0
7	Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer. <i>ESMO Open</i> , 2021, 6, 100094.	4.5	8
8	PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy as first-line treatment for advanced nonsquamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21152-e21152.	1.6	0
9	Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 733276.	2.8	3
10	Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 1173.	4.8	26
11	Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). <i>Frontiers in Oncology</i> , 2020, 10, 654.	2.8	52
12	Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2391-2400.	2.8	19
13	GLI1 activation is a key mechanism of erlotinib resistance in human non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 20, 76.	1.8	8
14	Efficacy and safety of SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous cell carcinoma: A phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21587-e21587.	1.6	0
15	PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/ β -catenin signaling. <i>Cancer Letters</i> , 2019, 450, 132-143.	7.2	66
16	Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. <i>Cancer Medicine</i> , 2019, 8, 1467-1473.	2.8	100
17	Comprehensive analysis of age-related somatic mutation profiles in Chinese young lung adenocarcinoma patients. <i>Cancer Medicine</i> , 2019, 8, 1350-1358.	2.8	16
18	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. <i>Cancer Research</i> , 2019, 79, 125-132.	0.9	56

#	ARTICLE	IF	CITATIONS
19	The risk variant rs884225 within EGFR impairs miR-103a-3p's anti-tumorigenic function in non-small cell lung cancer. <i>Oncogene</i> , 2019, 38, 2291-2304.	5.9	19
20	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. <i>Oncolmunology</i> , 2018, 7, e1376156.	4.6	14
21	Early versus late prophylactic cranial irradiation in patients with extensive small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 876-885.	2.0	10
22	Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer. <i>Cancer Gene Therapy</i> , 2017, 24, 57-63.	4.6	55
23	Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer. <i>Scientific Reports</i> , 2017, 7, 10760.	3.3	16
24	Harnessing plasma genotyping for precision therapy against lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E1387-E1390.	1.4	0
25	MicroRNA-205 increases the sensitivity of docetaxel in breast cancer. <i>Oncology Letters</i> , 2016, 11, 1105-1109.	1.8	13
26	Prolonged overall survival in gastric cancer patients after adoptive immunotherapy. <i>World Journal of Gastroenterology</i> , 2015, 21, 2777.	3.3	27
27	The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. <i>Oncotarget</i> , 2015, 6, 18997-19005.	1.8	28
28	MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. <i>Oncotarget</i> , 2015, 6, 25266-25280.	1.8	134
29	A study on the effect of ethanol extract of <i>Radix rhapontici</i> on erythrocyte immune function in rats. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2014, 10, 538.	0.3	7
30	Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure. <i>Lung Cancer</i> , 2014, 83, 305-307.	2.0	13
31	Fatal Interstitial Lung Disease after Addition of Sorafenib to a Patient with Lung Adenocarcinoma Who Had Failed to Improve with Erlotinib Alone. <i>Case Reports in Oncology</i> , 2014, 7, 273-276.	0.7	4
32	Study on anti-tumor effect of <i>Solanum Lyratum</i> thunb. Extract in S&sub&180&sub& tumor-bearing mice. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2013, 10, .	0.3	5
33	Detection of T lymphocyte subsets in the peripheral blood of patients with advanced lung adenocarcinoma. <i>Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae</i> , 2012, 34, 234-8.	0.2	0
34	PTK2 Promotes Hepatocellular Carcinoma Cancer Stem Cell Traits and Tumorigenicity by Activating Wnt/ β -Catenin Signaling. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
35	Dynamics of Serum Tumor Markers Predict Benefit from Immune Checkpoint Inhibitors in Chinese Patients with Advanced Non-Small Cell Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
36	Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Outcomes of Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Immune Checkpoint Inhibitors (ICIs). <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
37	Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7